Are Eticovo and Rinvoq the Same Thing?
Rinvoq (upadacitinib) and Eticovo (etanercept-ykro) are used to treat rheumatoid arthritis.
Eticovo is also used to treat polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and plaque psoriasis (PsO) in patients 4 years or older.
Eticovo is biosimilar to Enbrel (etanercept).
Rinvoq and Eticovo belong to different drug classes. Rinvoq is a Janus kinase (JAK) inhibitor and Eticovo a tumor necrosis factor (TNF) blocker.
Side effects of Rinvoq and Eticovo that are similar include infections (such as upper respiratory infections, nasopharyngitis, sinusitis, and influenza) and fever.
Side effects of Rinvoq that are different from Eticovo include nausea and cough.
Side effects of Eticovo that are different from Rinvoq include injection site reactions, diarrhea, rash, itching, and hives.
Both Rinvoq and Eticovo may interact with live vaccines.
Rinvoq may also interact with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin).
Eticovo may also interact with anakinra, abatacept, and cyclophosphamide, and sulfasalazine.
What Are Possible Side Effects of Rinvoq?
Common side effects of Rinvoq include:
- upper respiratory tract infections,
- nausea,
- cough, and
- fever
What Are Possible Side Effects of Eticovo?
Side effects of Eticovo nclude<:/p>
- infections (such as upper respiratory infections, nasopharyngitis, sinusitis, and influenza),
- injection site reactions,
- diarrhea,
- rash,
- itching,
- fever, and
- hives
What Is Rinvoq?
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
What Is Eticovo?
Eticovo (etanercept-ykro) is a tumor necrosis factor (TNF) blocker indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and plaque psoriasis (PsO) in patients 4 years or older. Eticovo is biosimilar to Enbrel (etanercept).
What Drugs Interact With Rinvoq?
Rinvoq may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Rinvoq is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rinvoq and for 4 weeks following completion of therapy. It is unknown if Rinvoq passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Rinvoq, and for 6 days after the last dose.
What Drugs Interact With Eticovo?
Eticovo may interact with "live vaccines," anakinra, abatacept, and cyclophosphamide, and sulfasalazine. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Eticovo; it is unknown how it would affect a fetus. Eticovo passes into breast milk in low levels. Consult your doctor before breastfeeding.
How Should Rinvoq Be Taken?
The recommended dose of Rinvoq is 15 mg once daily. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.
How Should Eticovo Be Taken?
The dose of Eticovo to treat adult rheumatoid arthritis and psoriatic arthritis is 50 mg once weekly with or without methotrexate (MTX). The dose of Eticovo to treat ankylosing spondylitis is 50 mg once weekly. The dose of Eticovo to treat adult plaque psoriasis is 50 mg twice weekly for 3 months, followed by 50 mg once weekly. The dose of Eticovo to treat pediatric plaque psoriasis or plaque psoriasis (patients who weigh 63 kg or more) is 50 mg once weekly.
From 
Rheumatoid Arthritis Resources
Featured Centers
Health Solutions From Our Sponsors
All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).
Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.
Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.
The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.
As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.
Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.
If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.
You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.
FDA. Rinvoq Product Information.
https://www.rinvoq.com
FDA. Eticovo Product Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761066s000lbl.pdf